Figure 4
Figure 4. Expression of LDOC1 mRNAs measured by QRT-PCR assay. (A) Expression of total LDOC1 mRNA. We used a commercially available assay that does not distinguish between the LDOC1 and LDOC1S mRNA isoforms. (B) Expression of wild-type LDOC1 and LDOC1S mRNA isoforms. We designed an assay that distinguishes between the isoforms. In both experiments, expression was measured in carcinoma (HeLa, MCF7) and lymphoma (GA10, Jurkat) cell lines, unfractionated normal peripheral blood B cells (NBC4, NBC6), normal peripheral blood B cells enriched for memory B cells (NBC9M, NBC10M, NBC11M, NBC13M), normal peripheral blood B cells enriched for naive B cells (NBC9N, NBC10N, NBC11N, NBC13N), and unmutated (U) or mutated (M) CLL and primary B-cell lymphoma samples, including follicular (FL), mantle cell (MCL), marginal zone (MZL), or splenic marginal zone (SMZL) lymphoma samples. Error bars represent the SE of the ΔΔCt values.

Expression of LDOC1 mRNAs measured by QRT-PCR assay. (A) Expression of total LDOC1 mRNA. We used a commercially available assay that does not distinguish between the LDOC1 and LDOC1S mRNA isoforms. (B) Expression of wild-type LDOC1 and LDOC1S mRNA isoforms. We designed an assay that distinguishes between the isoforms. In both experiments, expression was measured in carcinoma (HeLa, MCF7) and lymphoma (GA10, Jurkat) cell lines, unfractionated normal peripheral blood B cells (NBC4, NBC6), normal peripheral blood B cells enriched for memory B cells (NBC9M, NBC10M, NBC11M, NBC13M), normal peripheral blood B cells enriched for naive B cells (NBC9N, NBC10N, NBC11N, NBC13N), and unmutated (U) or mutated (M) CLL and primary B-cell lymphoma samples, including follicular (FL), mantle cell (MCL), marginal zone (MZL), or splenic marginal zone (SMZL) lymphoma samples. Error bars represent the SE of the ΔΔCt values.

Close Modal

or Create an Account

Close Modal
Close Modal